Glenmark Gets Early Win In Challenge To Merck's Zetia Patent Claims
This article was originally published in PharmAsia News
India's Glenmark Phrmaceuticals has won a favorable decision in a U.S. court against Merck and its patents on Zetia (ezetimibe) for controlling cholesterol
You may also be interested in...
Risk, Reward Sharing Extends To Generics: Glenmark, Par Tango As Lanuch Prospects For Zetia Copies Brighten
MUMBAI - Its raining deals for the Indian drug maker Glenmark. A day after the $450 million generics-cum-innovation driven pharma signed an out-licensing agreement with Sanofi Aventis for a novel research compound in pain management, it has now announced another one-of-its-kind licensing agreement - this time with Par Pharma to market generic versions of Merck/Schering Plough's $1.4 billion cholesterol drug Zetia (ezetimibe) in the United States
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.